AbbVie Inc. and Biogen Inc. are withdrawing marketing authorizations worldwide for multiple sclerosis treatment Zinbryta due to safety issues.
The withdrawal comes after reports of encephalitis, a swelling of the brain, and meningoencephalitis, an inflammation of brain tissue and the spinal cord, were associated with the drug.
The European Medicines Agency previously recommended that use of the drug be restricted to patients that had an inadequate response to two other multiple sclerosis treatments after the death of a patient and four cases of serious liver injury.
